Larimar Therapeutics Executive Compensation (FY25)
LRMR · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Carole Ben-Maimon | Latest say-on-pay support = May 19, 2026 |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The paid brief on Larimar Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
Data as of October 30, 2026Latest filing (8-K): May 19, 2026
12 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
180 figures on this page: 174 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
More on Larimar Therapeutics
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Carole Ben-Maimon: $2,511,649 → $3,526,423 (40.4% higher)
Say-on-pay support: 97.1% → 98.0% (0.9 points higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Larimar Therapeutics' chief executive and what were they paid?
Carole Ben-Maimon was paid $3,526,423 in total compensation as President and Chief Executive Officer for fiscal 2025. Ben-Maimon's total moved 40.4% higher from the $2,511,649 reported for fiscal 2024.
What was Larimar Therapeutics' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 98.0% of votes cast for or against in favor at the meeting held May 19, 2026.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Carole Ben-Maimon President and Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Michael Celano Chief Financial Officer and Secretary | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Carole Ben-Maimon President and Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Michael Celano Chief Financial Officer and Secretary | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Gopi FAAPS Chief Development Officer (8) | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Carole Ben-Maimon President and Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Michael Celano Chief Financial Officer and Secretary | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Gopi Shankar Chief Development Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Carole Ben-Maimon President and Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Michael Celano Chief Financial Officer and Secretary | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Gopi Shankar Chief Development Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Carole S. Ben-Maimon | PRSU | — | — | — | — | — | — | ◇ |
| Carole S. Ben-Maimon | OPTION | — | — | — | — | — | — | ◇ |
| Gopi Shankar | PRSU | — | — | — | — | — | — | ◇ |
| Gopi Shankar | OPTION | — | — | — | — | — | — | ◇ |
| Michael Celano | OPTION | — | — | — | — | — | — | ◇ |
| Michael Celano | PRSU | — | — | — | — | — | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Carole Ben-Maimon | Option | ◇ | — | ◇ | 1/22/2035 |
| Option | ◇ | — | ◇ | 1/17/2034 | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/31/2033 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 5/10/2032 | |
| Option | ◇ | — | ◇ | 1/18/2032 | |
| Michael Celano | Option | ◇ | — | ◇ | 1/22/2035 |
| Option | ◇ | — | ◇ | 1/17/2034 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/31/2033 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 5/10/2032 | |
| Option | ◇ | — | ◇ | 1/18/2032 | |
| Gopi Shankar | Option | ◇ | — | ◇ | 1/22/2035 |
| Option | ◇ | — | ◇ | 2/7/2033 | |
| Option | ◇ | — | ◇ | 1/17/2034 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Carole Ben-Maimon
President and Chief Executive Officer · Employment agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
| Clawback | ◇ |
Gopi Shankar
Chief Development Officer
| Excise tax treatment | ◇ |
Michael Celano
Chief Financial Officer and Secretary · Employment agreement
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
| Non-compete period | ◇ |
| Non-solicit period | ◇ |
| Clawback | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Joseph Truitt Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Frank Thomas | ◇ | — | ◇ | — | — | — | ◇ |
Jonathan Leff | ◇ | — | ◇ | — | — | — | ◇ |
Thomas E. Hamilton | ◇ | — | ◇ | — | — | — | ◇ |
Jeffrey W. Sherman, M.D., FACP | ◇ | — | ◇ | — | — | — | ◇ |
Carole S. Ben-Maimon, M.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 19, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 13, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 29, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 9, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 10, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 12, 2021 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Carole Ben-Maimon (President and Chief Executive Officer), FY2025 total compensation $3,526,423 (base salary $650,000) [exec_comp, SEC accession 0001193125-26-163942, filed 2026-04-20]What this page does not include
Everything above is a fact Larimar Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
180 figures on this page: 174 cited to the filing that reported them, 6 calculated from figures it prints.
174 cited to the filing
6 calculated from the filing
Documents cited
- 0001193125-26-230852Proposal 2 - Approval, on an advisory basis, of the compensation of the Company’s named executive officers in 2025.
- 0001193125-26-1639422025 SUMMARY COMPENSATION TABLE · DIRECTOR COMPENSATION · OUTSTANDING EQUITY AWARDS AT FISCAL 2025 YEAR-END · SUMMARY COMPENSATION TABLE
- 0000950170-25-070287Proposal 2 - Approval, on an advisory basis, of the compensation of the Company’s named executive officers in 2024.
- 0000950170-25-0530282024 SUMMARY COMPENSATION TABLE
- 0000950170-24-067306
- 0001193125-24-1221912023 SUMMARY COMPENSATION TABLE
- 0000950170-23-021747
- 0000950170-23-007855
- 0001193125-22-148643
- 0001193125-21-162647
- 0001193125-20-211426Exhibit
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Larimar Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/LRMR (accessed 2026).
Short form: data: Velarion
The paid brief for Larimar Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
12 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Larimar Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}